Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes.
Fatemeh Baharvand, Roxana Mehran, Francesca Maria Di Muro et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of empagliflozin on left ventricular ejection fraction (LVEF) recovery and major adverse cardiac events (MACE) in 117 patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Empagliflozin significantly improved LVEF recovery at day 40, with a mean increase of 7.35% compared to 2.96% in the placebo group (mean difference 4.39%, P = 0.000272).
Key findings
- Empagliflozin led to a mean LVEF increase of 7.35% compared to 2.96% in the placebo group.
- The adjusted mean difference in LVEF recovery was 3.44% (P = 0.003).
- MACE rates were 3.8% in the empagliflozin group versus 7.5% in the placebo group (P = 0.68).
- No significant adverse events were reported, including diabetic ketoacidosis or acute kidney injury.
Why it matters
The study suggests that empagliflozin may enhance cardiac recovery following STEMI, potentially improving early prognostic outcomes. Understanding its role in this acute setting could inform treatment strategies for patients post-myocardial infarction.